Herein, we investigated the contribution of NOX1 in obesity-associated hypertension and evaluated the therapeutic potential of pharmacologically targeting NOX1 using the novel inhibitor GKT771. This evidence concerns the gene NOX1 and obesity due to melanocortin 4 receptor deficiency.